Compare Cassava Sciences Inc (FLNA) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Union Pacific Corporation — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Union Pacific Corporation trades at $278.34 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 4194.7× Cassava Sciences Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Union Pacific Corporation for 105 Days on average.
| FLNA | UNP | |
|---|---|---|
Market Cap | $39.40M | $165.27B |
Volume | 759,018 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $4.64 | $310.62 |
52-Week Low | $0.68 | $216.37 |
Typical Hold Time | 37 Days | 105 Days |
Enterprise Value | -$43.28M | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.
The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.
Union Pacific (UNP) trades at $278.20, up 1.28% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, and the company maintains robust profitability with a 28.85% net margin and 39.7% ROE. Positive sentiment is driven by volume growth, a pending Norfolk Southern merger, and dividend reliability, though merger uncertainty and fuel costs pose risks.
Outlook is positive given earnings momentum and strategic initiatives, but investors face risks from merger execution and economic cyclicality. The stock offers value with a consensus price target of $332.10, implying significant upside, supported by stable cash flows and a solid dividend track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
